Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trial
read at Endpoints ↗Negative readoutNegative
Novo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial.
The study was intended to demonstrate that reducing inflammation would lower the risk of heart disease, but the results showed no statistically significant benefit compared with placebo.
The failure represents a setback for the Danish company's cardiovascular pipeline and may prompt a reassessment of its strategy in this therapeutic area.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo Nordisk rocked by late-stage cardiovascular drug failure”
read at Endpoints ↗80 words · retrieved Jul 31
comments(0)
5-min edit window · permanent after that